Cytomegalovirus infection and disease after liver transplantation - An overview

Robert J. Stratta, Mark S. Shaeffer, Rodney S. Markin, R. Patrick Wood, Alan N. Langnas, Elizabeth C. Reed, Jeremiah P. Donovan, Gail L. Woods, Kathleen A. Bradshaw, Todd J. Pillen, Byers W. Shaw

Research output: Contribution to journalReview articlepeer-review

87 Scopus citations


Cytomegalovirus is the single most important pathogen in clinical transplantation. Although much progress has been made in our understanding of the molecular biology and epidemiology of CMV infection and in our ability to diagnosis and treat CMV disease, it remains a major cause of morbidity but is no longer a major cause of mortality after liver transplantation. Risk factors for CMV disease after liver transplantation include donor and recipient serologic status, the use of antilymphocyte therapy, and retransplantation. CMV disease occurs early after transplantation, and the most frequent site of disease is the hepatic allograft. We have treated 79 patients with intravenous ganciclovir, with ultimate control of disease achieved in 69 patients (87.3%). Preliminary results using intravenous immunoglobulin and oral acyclovir for CMV prophylaxis in high-risk patients have been encouraging. In addition to producing clinical syndromes, CMV may have direct immunologic effects and is a marker of the net state of immunosuppression.

Original languageEnglish (US)
Pages (from-to)673-688
Number of pages16
JournalDigestive Diseases and Sciences
Issue number5
StatePublished - May 1992


  • OKT3
  • acyclovir
  • cytomegalovirus
  • ganciclovir
  • immunoglobulin
  • immunosuppression
  • liver transplantation

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology


Dive into the research topics of 'Cytomegalovirus infection and disease after liver transplantation - An overview'. Together they form a unique fingerprint.

Cite this